Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GI-5005: Interim Phase II data

Interim data from 93 patients in an open-label Phase II trial showed GI-5005 plus pegylated interferon and ribavirin

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE